Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Bourla and Afeyan said they began talking about this new approach in the depths of the pandemic, when they were “partners-slash-competitors,” as Bourla puts it, in the effort to create a vaccine.

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

The NHS spring booster campaign will offer jabs to limited groups of vulnerable patients from 1 April. More than 9.7 million ...

Pfizer’s adjusted fourth-quarter profit of 63 cents a share beat the FactSet consensus estimate of 47 cents a share. Revenue rose to $17.76 billion from $14.57 billion, and beat the FactSet consensus ...